Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Combination REOLYSIN(R) and Docetaxel Results at iSBTc Annual Meeting
Date:10/23/2008

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced today that an abstract entitled "A Phase I Study to Evaluate Systemic Wild-Type Reovirus (REOLYSIN(R)) in Combination with Docetaxel in Patients with Advanced Malignancies" will be available in the November/December issue of the Journal of Immunotherapy, the official journal of the International Society for Biological Therapy of Cancer (iSBTc). The principal investigator for the trial is Professor Hardev Pandha of the Royal Surrey County Hospital, U.K.

The abstract covers results of the trial (REO 010) up to July 2008. Of the 12 patients treated at the time, three had completed six cycles, one further patient was still on treatment at cycle 7 and four others were ongoing between cycle 1 and cycle 4. Five patients remained on study. The researchers observed one complete resolution of the target lesion in a breast cancer patient with stable disease (SD) of non-target lesions; one partial response in gastric cancer; two SD in lung cancer; and, one SD in melanoma. The researchers concluded that REOLYSIN(R) can be safely combined with docetaxel, that there was objective radiological evidence of anticancer activity and that Phase II studies with this combination are justified. Any significant toxicities observed were consistent with those expected with docetaxel alone.

A poster presentation which will include current results of the trial is scheduled to be presented by Prof. Pandha on November 1, 2008 at the iSBTc annual meeting. The meeting is being held in San Diego, California from October 31-November 2, 2008.

Prof. Pandha is also scheduled to make a poster presentation on November 1, 2008 at the iSBTc meeting entitled "Synergistic Anti-Tumour Activity of Oncolytic Reovirus and Docetaxel in a PC-3 Prostate Cancer Mouse Model." This preclinical research, which demonstrated that combining reovirus and docetaxel treatment resulted in markedly re
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Collaborators Present Reovirus and Melanoma Research at EORTC-NCI-AACR Symposium
2. Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
3. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2008
4. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
5. Oncolytics Biotech Inc. Completes Initial Scale Up of Manufacturing Process for REOLYSIN(R) to Commercial Scale
6. Media Advisory - Oncolytics Biotech Inc. to Present at Maxim Group Growth Conference
7. Oncolytics Biotech Inc. Announces Issuance of 28th U.S. Patent
8. Oncolytics Biotech Inc. Collaborators to Present REOLYSIN(R) Clinical Trial
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
11. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... Basel in Switzerland have succeeded in observing the ... the first time. These extremely weak spectra offer ... and may also contribute to the development of ... published in the scientific journal Nature Physics ... between matter and light, is probably the most ...
(Date:9/20/2014)... 20, 2014 HealthTronics, Inc. ... interventional radiology products and services, has signed a ... Clinicon Corporation for its high precision ... of minimally invasive, mobile, surgical technology—offering more choices ... the agreement, HealthTronics will make available Clinicon’s FDA-cleared ...
(Date:9/19/2014)... NEW YORK, September 18, 2014 Scientists at NYU ... boost dramatically the efficiency of the process for turning ... three well-known compounds, including vitamin C. Using the new ... stem cells obtained from adult skin cells by more ... their technique is efficient and reliable, and thus should ...
(Date:9/19/2014)... 19, 2014 Biotech companies make ... emerging drug systems and advanced Laboratory Instrumentation. Companies in ... (NYSE: BDX ), Thermo Fisher Scientific Inc. ... RGDO ), Sangamo Biosciences Inc. (NASDAQ: ... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the ...
Breaking Biology Technology:Uncovering the forbidden side of molecules 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3NYU Langone scientists report reliable and highly efficient method for making stem cells 2NYU Langone scientists report reliable and highly efficient method for making stem cells 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 2Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 3Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 4Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 5Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 6Medical Instrumentation Automation Advances for Biological Sample Preparation - Company Expects Q4 Revenue Impact from Newest Instrument Systems 7
... - From less than 1 million to 600 ... growth in the past 10 years. , ,From the ... job, providing better tools for finding, filtering and presenting ... decade on the Web and also looking forward to ...
... Madison, Wis. - Stratatech Corporation , a UW ... from the National Institute on Aging, for the development of ... wounds such as diabetic, venous stasis and pressure ulcers, which ... estimated that in the United States alone, millions of people ...
... Madison, Wis. Pierce Biotechnology , a ... BioSurfaces of Madison, Wis., to distribute GenTel's trademarked ... use of GenTel technology in developing new protein arrays ... specifically designed for protein-array applications, including the profiling of ...
Cached Biology Technology:Internet Scout celebrates 10 years on web, eyes new project launch 2
(Date:9/22/2014)... New Haven, Conn. Yale University researchers are studying ... pulmonary fibrosis, a respiratory disease in which scars develop ... treatment uses a microRNA mimic, miR-29, which is delivered ... only blocked pulmonary fibrosis, it reversed fibrosis after ... in the journal EMBO Molecular Medicine . , ...
(Date:9/22/2014)... molecular cog in a plant,s biological clock one ... on temperature. , Transcription factors, or genetic switches, drive ... such as light, rain, soil quality, or even animals ... has isolated one, called FBH1, that reacts to temperature ... while in keeping it on a consistent track. , ...
(Date:9/22/2014)... of the fires captured in this image burn in Khabarovsk ... Okhotsk. Dozens of red hotspots, accompanied by plumes of smoke ... grey, blows to the east towards the Sea of Okhotsk. ... of this area, swampy forest inhabit the central depression, and ... While large wildfires are common in Russia in the summer, ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Genetic switch regulates a plant's internal clock based on temperature 2
... Recognizes Leadership in Technology and Innovation in Global ... LMT ) has been named the ... Frost and Sullivan, recognizing the Corporation,s leadership in ... of customers. Frost and Sullivan based the award ...
... The Centre for Genomic Regulation (CRG) in Barcelona, Spain ... by Genomatix Software GmbH. , GGA comprises purpose built ... software providing a complete solution for the analysis of ... genome. "In regards to the machine, I love ...
... 4, 2009 The incidence of pneumothorax (PTX), or collapsed ... has been reported to range from 13 50 percent, ... In people, PTX is reported to be the most preventable ... ultrasound has been infrequently used as a non-invasive, point-of-care imaging ...
Cached Biology News:Lockheed Martin Named Biometrics 'Company of the Year' by Frost and Sullivan 2CRG buys Genomatix' Next Generation Sequencing analysis solution 2Novel veterinary procedure detecting life-threatening injuries touted 2
... HVJ (hemagglutinating virus of Japan, also named ... tool for transfection of molecules by means ... for siRNA (RNAi), Protein, Oligo, cDNA, Antibodies, ... in vivo. GenomONE-Neo EX has a high ...
... Whole Genome ChIP-on-chip Microarray is specifically ... (S. cerevisiae) DNA binding proteins by ... DNA microarrays. This set delivers robust ... greater true binding events and fewer ...
... Faster speeds, highest precision, more ... flexible concept: this is the definition of ... few years nucleic acid research has been ... capabilities required of PCR Systems. To ...
... genomics-based research with S. aureus, Sigma-Genosys has developed ... primers to amplify all open reading frames (ORFs) ... are included to amplify ORFs that are unique ... S. aureus. The ORFmer set contains primers to ...
Biology Products: